[Recommendations for good practice: drug therapy for genital endometriosis (except adenomyosis) (November 2005)]

Agence Françaises de sécurité sanitaire des produits de santé, Afssaps, P Madélénat
Gynecologie, obstetrique & fertilite · 2006 · vol. 34(1) , pp. 70 · doi:10.1016/j.gyobfe.2005.12.008 · PMID:16406660 · W2401728740
Guideline OA: closed CC0 ⤵ 4 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This paper discusses the Afssaps's 2005 good practice recommendations for medical treatments of endometriosis, excluding adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Practice Patterns, Physicians' Practice Patterns, Physicians' Danazol Danazol Danazol Endometriosis Endometriosis Estrogen Antagonists Estrogen Antagonists Estrogen Antagonists Female Female Humans Humans Progestins Progestins Progestins Treatment Outcome Treatment Outcome

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (4)

Cited by (4)

Source provenance

europepmc
last seen: 2026-10-20T06:13:28.455750+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:03:30.943773+00:00
License: CC0 · commercial use OK